Lactose (India) Ltd
NSE: BSE: 524202
₹86.11
(-4.83%)
Sun, 29 Mar 2026, 06:23 pm
Market Cap1.08B
PE Ratio23.02
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KLactose (India) Analysis
dividend
- Unable to evaluate Lactose (India)'s dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Lactose (India)'s dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Lactose (India) is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Lactose (India) has been profitable on average in the past, therefore cash runway is not a concern.
- Lactose (India) has been profitable on average in the past, therefore cash runway is not a concern.
- The level of debt compared to net worth has been reduced over the past 5 years (242.1% vs 111.9% today).
- Debt is not well covered by operating cash flow (5%, less than 20% of total debt).
- Debt is not covered by short term assets, assets are 0.6x debt.
- Lactose (India)'s long term commitments exceed its cash and other short term assets.
- Lactose (India) is making a loss, therefore interest payments are not well covered by earnings.
- Lactose (India)'s level of debt (111.9%) compared to net worth is high (greater than 40%).
- High level of physical assets or inventory.
management
- The tenure for the Lactose (India) board of directors is about average.
- The tenure for the Lactose (India) management team is about average.
- Atul's remuneration is higher than average for companies of similar size in India.
- Atul's compensation has increased whilst company is loss making.
misc
- Lactose (India) is not covered by any analysts.
past
- Unable to compare Lactose (India)'s 1-year earnings growth to the 5-year average as it is not currently profitable.
- Lactose (India) does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- Lactose (India) used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- It is difficult to establish if Lactose (India) improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
- It is difficult to establish if Lactose (India) has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- Unable to compare Lactose (India)'s 1-year growth to the IN Pharmaceuticals industry average as it is not currently profitable.
value
- Lactose (India) is good value based on assets compared to the IN Pharmaceuticals industry average.
- Lactose (India) is loss making, we can't compare its value to the IN Pharmaceuticals industry average.
- Lactose (India) is loss making, we can't compare the value of its earnings to the India market.
- 524202 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- 524202 underperformed the Market in India which returned -14.5% over the past year.
- BSE:524202 is flat (-0.3%) underperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:524202 is flat (-0.3%) underperforming the market in India which returned 8% over the past month.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800